BofA moved to No Rating on KalVista (KALV) Pharmaceuticals after the company agreed to be acquired by Italian company Chiesi Group for $27 per share. KalVista is no longer trading on fundamentals, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALV:
- Chiesi to Acquire KalVista Pharmaceuticals in Cash Merger
- Chiesi Group to acquire KalVista for $27.00 per share in cash
- 3 ‘Strong Buy’ Stocks With Up to 180% Upside to Buy Now, According to Top Analysts, 4/16/2026
- Ekterly: Strong Global Launch Momentum and Pediatric Upside Support Multi‑Year Growth and $39 Price Target
- KalVista announces interim Phase 3 data from KONFIDENT-KID trial of EKTERLY